Global sale of Celltrion's COVID-19 antibody-drug Regkirona begins

Worldwide sales of Regkirona (active ingredient: regdanvimab), a COVID-19 antibody drug developed by South Korean biopharmaceutical company Celltrion Inc, has begun. Celltrion Healthcare Co Ltd, the marketing arm of Celltrion, announced on Monday that it has signed a contract with a Pakistani state-owned company to export 100,000 vials of Regkirona. The total supply is a sufficient amount to administer to about 30,000 people. The contractee is a subsidiary of Pakistan Ordnance Factories (POF), the largest defense contractor under Pakistan's Ministry of National Defense. 

from IndiaTV World: Google News Feed https://ift.tt/33yOgMj